IDT Bolsters CRISPR Portfolio with SeQure Dx Licensing Deal
24 Jul 2024 //
CONTRACT PHARMA
IDT And SeQure Dx Sign Licensing Agreement For CRISPR Therapeutics
15 Jul 2024 //
BUSINESSWIRE
SeQure Dx to present at (ASGCT) on the importance gene editing and cell therapy
03 May 2023 //
BUSINESSWIRE

Market Place
Sourcing Support